GleamWall
中文EN

NVS NOVARTIS AG IFRS

Pharmaceutical Preparations · NYSE · SEC CIK 1114448 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY8.4%
TTM net income YoY17.1%
TTM EPS YoY21.8%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR26.2%

Margins

Gross margin78.8%
Operating margin32.4%
Net margin25.6%
FCF margin32.3%
EBITDA margin—

Returns

ROE31.0%
ROA13.1%
ROIC (approx.)44.8%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.00x
Current ratio1.12x
Interest coverage15.42x

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-4.8%
Payout ratio55.9%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$54.53B$50.32B
Cost of revenue$13.70B$12.83B
Gross profit$42.98B$38.90B
R&D expense$11.20B$10.02B
SG&A expense$13.25B$12.57B
Operating income$17.64B$14.54B
Interest expense$1.14B$1.01B
Pretax income$16.35B$13.64B
Income tax$2.38B$1.70B
Net income$13.98B$11.94B
EPS (basic)7.215.92
EPS (diluted)7.155.87
Weighted avg. shares (diluted)1.96B2.04B
Balance sheet
Cash & equivalents$11.44B$11.46B
Short-term investments$98.00M$1.89B
Receivables$8.94B$7.42B
Inventory$6.27B$5.72B
Current assets$30.46B$29.70B
PP&E, netmay include right-of-use assets (IFRS)$10.78B$9.46B
Goodwill$25.57B$24.76B
Intangibles$29.41B$26.91B
Total assets$110.95B$102.25B
Current liabilities$27.28B$28.69B
Short-term debt$682.00M$642.00M
Total liabilities$64.40B$58.12B
Shareholders' equity$46.13B$44.05B
Shares outstanding1.91B1.98B
Cash flow statement
Operating cash flow$19.14B$17.62B
Capital expenditure$1.55B$1.37B
Free cash flow$17.60B$16.25B
Investing cash flow-$4.88B-$7.51B
Financing cash flow-$14.87B-$11.74B
Stock-based compensation$1.10B$1.04B
Dividends paid$7.82B$7.62B
Share buybacks$9.21B$8.33B

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.